Advertisement

Clinical Rheumatology

, Volume 36, Issue 7, pp 1691–1692 | Cite as

Response to “Vaccine-related serious adverse events might have been under-recognized in the pivotal HPV vaccine randomized trial”

  • David Hawkes
Letter to the Editor

Keywords

Hypersensitivity Reaction Gastrointestinal Disorder European Medicine Agency Anaphylactic Reaction Complex Regional Pain Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Compliance with ethical standards

Disclosures

None.

References

  1. 1.
    Martinez-Lavin M (2017) Vaccine-related serious adverse events might have been under-recognized in the pivotal HPV vaccine randomized trial. Clin Rheumatol. doi: 10.1007/s10067-017-3575-z Google Scholar
  2. 2.
    Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A, Broad Spectrum HPVVS (2015) A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372(8):711–723. doi: 10.1056/NEJMoa1405044 CrossRefPubMedGoogle Scholar
  3. 3.
    Petousis-Harris H (2016) Proposed HPV vaccination syndrome is unsubstantiated. Clin Rheumatol 35(3):833–834. doi: 10.1007/s10067-015-3090-z CrossRefPubMedGoogle Scholar
  4. 4.
    European Medicines Agency (2015) Assessment report. Review under Article 20 of Regulation (EC) No 726/2004 EMA, London. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/HPV_vaccines_20/Opinion_provided_by_Committee_for_Medicinal_Products_for_ Human_Use/WC500197129.pdf. 03/03/2017

Copyright information

© International League of Associations for Rheumatology (ILAR) 2017

Authors and Affiliations

  1. 1.University of MelbourneMelbourneAustralia

Personalised recommendations